An experimental drug developed from research at the Medical University of South Carolina is showing early promise for some patients with advanced prostate cancer whose disease no longer responds to standard hormone therapies. In a Phase 2 clinical trial, researchers tested opaganib in combination with existing treatments and found that a subset of patients experienced encouraging signs that the therapy may be slowing the disease, including drops in blood markers linked to prostate cancer and periods of disease stabilization. Researchers are now analyzing blood samples from patients in the trial to identify biomarkers that could help predict who is most likely to benefit from the treatment. The findings could help advance a more personalized approach to prostate cancer care while opening the door to future therapies targeting the same biological pathway.

Florida State University researchers have discovered how to accurately predict winter weather forecasts months in advance, affording sectors such as agriculture, water management, energy use and public health a longer lead time to prepare for inclement conditions.

A single dose of the psychedelic substance psilocybin can provide rapid relief from depressive symptoms – within just a few days. This is shown by the first randomised, double-blind study in Sweden of psilocybin for depression. The effect persisted for over three months, according to researchers at Karolinska Institutet.

Rolling bearings are critical components in heavy machinery, and their lubricant film thickness directly determines equipment reliability. This new study introduces a coupled elastohydrodynamic–acoustic framework for high-resolution, noninvasive ultrasonic measurement of dynamic oil film thickness in bearings. By accounting for elastic deformation and cavitation, the method greatly improves measurement accuracy and supports real-world industrial monitoring. It offers a practical way to assess bearing health and enhance operational stability.